Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412965 · ClinicalTrials.gov registry record
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 528
- Enrollment target
NCT06412965 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 528 participants.
The verdict
NCT06412965 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 528 participants
- Enrollment target
Study Summary
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2024-01-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06412965
The ClinicalTrials.gov registry entry for NCT06412965 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 528 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06412965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06412965 about?
NCT06412965 is a clinical study titled "Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine". This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
What is the current status of trial NCT06412965?
This trial is currently completed. The enrollment target is 528 participants. The study started on 2024-01-02. Estimated completion is 2024-01-03.
Who is sponsoring clinical trial NCT06412965?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.